Novartis

Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

More... »

FDA approves Gleevec for rare gastrointestinal cancer

Thursday, February 2, 2012 08:32 AM

The FDA has granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

Novartis to restructure, cut 1,960 jobs

Thursday, January 19, 2012 09:30 AM

Novartis has announced plans to strengthen its long-term competitive position and reduce its cost base with a restructuring of U.S. operations.

More... »

FDA says Opioids may be found in Novartis OTC drugs

Wednesday, January 11, 2012 11:25 AM

The FDA has released an advisory regarding the Novartis recall due to the mixed bottling of products. While previous reports suggested that the OTC drugs NoDoz, Excedrin, Bufferin and Gas-X had simply been mixed with each other, the FDA now is warning patients that high-powered, prescription-only opioid drugs may have found their way into Novartis OTC packaging.

More... »

Novartis recalls OTC drugs, temporarily closes U.S. plant

Monday, January 9, 2012 01:51 PM

Novartis is recalling several over-the-counter products such as Gas-X, Excedrin, NoDoz, and Bufferin due to inconsistent bottling, as well as broken gel caps and chipped pills.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »

Drug sponsors join research partnership to accelerate drug discovery

Thursday, September 29, 2011 01:21 PM

In a bid to save both time and money, some of the industry's biggest names are experimenting with new ways to pool early-stage research, effectively taking a leaf out of the "open-source" manual that gave the world Linux software, according to Reuters.

More... »